- $1.92bn
- $1.57bn
- $125.58m
Brief: Xencor Doses First Subject In Phase 1/2 Study Of Xmab®942 In Development For Patients With Inflammatory Bowel Disease
U.S. RESEARCH ROUNDUP- ANI Pharmaceuticals, Deere & Co, Zoetis
Brief: Xencor Announces Pricing Of $175 Million Public Offering Of Common Stock
Brief: Xencor Announces Proposed Public Offering Of Common Stock
Brief: Zenas Biopharma Files For IPO - SEC Filing
Brief: Xencor Q2 Net Income USD -67.408 Million
Xencor Inc expected to post a loss of 86 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Adobe, Oracle Corp, Zscaler
Brief: Xencor Q1 Revenue USD 12.805 Million Vs. IBES Estimate USD 25 Million
Xencor Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Oncology Firm Xencor Names Former Seagen Exec Bart Cornelissen As CFO
Xencor Inc reports results for the quarter ended in December - Earnings Summary
Brief: Xencor Q4 Net Income USD -19.263 Million
Xencor Inc expected to post a loss of 9 cents a share - Earnings Preview
Xencor Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Xencor Says New Collaboration Agreement Effective June 1, 2024, To Replace Current Collaboration And License Agreement Between Co And Roche
Brief: Xencor Q3 EPS USD -0.4
Xencor Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Xencor Announces Planned Retirement Of Chief Financial Officer John Kuch